SCHOTT Pharma stock (DE000A3ENQ51): Pharmaceutical packaging specialist with global reach

SCHOTT Pharma develops and manufactures primary packaging for injectable pharmaceuticals, including glass and polymer syringes, vials, and cartridges. The company reported steady demand in its latest annual figures for fiscal year 2024, published March 2026, with revenue growth driven by biologics and insulin products, according to SCHOTT Pharma IR as of March 2026.

The stock traded at around 45.50 EUR on Xetra on May 12, 2026, reflecting stability in the medtech sector, per Börse Frankfurt as of May 12, 2026. This positions SCHOTT Pharma as a key supplier for US-listed pharma giants like Pfizer and Eli Lilly.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

SCHOTT Pharma: core business model

SCHOTT Pharma focuses on high-precision packaging for parenteral drugs, leveraging over 140 years of glass expertise from its parent SCHOTT AG. The business splits into two segments: Classic Packaging for standard syringes and vials, and Advanced Packaging for specialized polymer syringes used in high-volume injectors. This model targets pharma companies needing reliable, sterile containers for vaccines, insulins, and monoclonal antibodies.

In 2024, the company generated about 60% of revenue from Advanced Packaging, reflecting a shift toward complex biologics packaging, as detailed in its fiscal 2024 report published March 2026, according to SCHOTT Pharma IR as of March 2026. Production occurs at sites in Europe, the US, and India, ensuring proximity to key markets.

Main revenue and product drivers for SCHOTT Pharma

Key products include SCHOTT TopPac Nest 50 polymer syringes for autoinjectors and SCHOTT adapro prefillable syringes, which dominate in GLP-1 therapies like semaglutide. Demand surged post-COVID due to vaccine packaging needs, with biologics now accounting for over 40% of pipeline drugs. Revenue for fiscal 2024 reached €690 million, up 8% year-over-year for the period ended December 31, 2024, per the March 2026 annual report.

US exposure comes via facilities in Wilson, North Carolina, supplying domestic pharma firms. Partnerships with BD and West Pharma bolster its position in the $10 billion global prefillable syringe market, according to company filings as of March 2026.

Industry trends and competitive position

The pharmaceutical packaging sector grows at 7% CAGR through 2030, driven by biologics and self-injection devices, per Statista data published January 2026. SCHOTT Pharma holds 15-20% share in polymer syringes, competing with Gerresheimer and Stevanda. Its glass-to-polymer transition gives an edge in sustainability, with recyclable TopPac reducing plastic use by 30%.

Regulatory approvals like FDA nods for new vial lines enhance reliability for US customers. The company's 2025 capacity expansions target 20% output growth by 2027.

Why SCHOTT Pharma matters for US investors

US pharma represents 45% of SCHOTT Pharma's sales, tied to giants like Johnson & Johnson and Novo Nordisk. Listed on FSE since March 2023 IPO, it offers US investors access to medtech supply chain stability amid domestic shortages. Its €300 million+ EBITDA in 2024 underscores resilience in the $1.5 trillion US pharma market.

Conclusion

SCHOTT Pharma maintains a strong foothold in pharmaceutical packaging, with robust revenue from advanced syringes and vials serving global pharma needs. Its US production and ties to major drugmakers provide stability, though sector competition and regulatory shifts warrant monitoring. Investors follow its capacity expansions and biologics focus for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.